KRAS G12C
KRAS G12C refers to a specific oncogenic missense variant of the KRAS gene in which glycine at codon 12 is replaced by cysteine.
KRAS G12C refers to a specific oncogenic missense variant of the KRAS gene in which glycine at codon 12 is replaced by cysteine. This alteration affects the KRAS small GTPase, a central regulator of signaling pathways that control cell proliferation, survival, and differentiation, including downstream MAPK1-related signaling. In cancer biology, KRAS G12C is notable because the introduced cysteine creates a chemically addressable residue that has enabled the development of allele-specific covalent inhibitors, transforming KRAS from a long-considered undruggable target into a clinically actionable one.
Therapeutically, KRAS G12C has become an important target in tumors driven by KRAS-dependent signaling, especially lung adenocarcinoma and colorectal cancer, and it is also being investigated in gastrointestinal tumors and pancreatic cancer models. Current research emphasizes direct KRAS G12C inhibition, combination strategies with EGFR blockade, SOS1 inhibition, and approaches to overcome acquired resistance. Resistance remains a major challenge, with both genetic and non-genetic mechanisms reported in the setting of KRAS inhibition.
Where the papers sit
27 papers from the last 6 months study KRAS G12C directly · updated from PubMed 15 Nov 2026
Study type 0 clinical trials · 1 observational · 7 human data · 15 preclinical · 4 unclassified
Themes 4 themes · 1 paradigm shift · 1 new direction
-
KRAS Inhibition in Lung Cancer
KRAS G12C inhibition in NSCLC is moving from single agents toward combination strategies and new inhibitor chemotypes. FAK blockade, avutometinib, PRMT1 inhibition and EGFR-axis suppression are being explored to overcome adaptive or acquired resistance, including ferroptosis changes. Computational repurposing and predictive gene signatures broaden candidate selection, while covalent and noncovalent compounds seek better potency and CNS penetration. CRISPR-based ctDNA assays support mutation detection, but clinical validation remains open.
13 papers · 48.1%
-
KRAS Resistance in Digestive Cancers
Resistance to KRAS-directed therapy in colorectal and other digestive cancers is the dominant question, spanning genetic, non-genetic and adaptive escape. EGFR pathway alterations, subclonal anti-EGFR mutations and altered KRAS signaling recur, while farnesylation-driven phase separation offers a separate growth mechanism. Allele-specific strategies are expanding beyond G12C toward pancreatic cancer and KRASG12V degradation, but relapse after treatment remains evident. The relative value of combinations and resistance-guided sequencing is unresolved.
6 papers · 22.2%
-
SOS1 Inhibition in KRAS Cancer
SOS1 inhibition is emerging as a way to suppress KRAS-driven signaling beyond direct allele-specific blockade. Selective inhibitors are being optimized for colorectal cancer, with CNS penetration extending the approach to KRAS-dependent tumors in difficult compartments. Resistance can instead arise through EML4-ALK, which rewires signaling through wild-type RAS and creates a new dependency. How broadly SOS1 inhibitors can cover KRAS alleles such as G12D and overcome bypass signaling remains open.
4 papers · 14.8%
-
Others — Precision Oncology Therapeutics
Precision oncology here ranges from high-risk sarcoma biobanking to KRAS inhibitor resistance and treatment-response monitoring in gastrointestinal tumors. ecDNA-driven oncogene amplification in osteosarcoma and ATF3-dependent asparagine biosynthesis identify distinct therapeutic vulnerabilities. Circulating tumor-cell dynamics during glecirasib treatment are being used to associate evolutionary change with survival and resistance. The conference synthesis and antibody-drug conjugate discussions broaden the set beyond a single disease or mechanism.
4 papers · 14.8%
KRAS G12C inhibitor resistance can be an early, reversible adaptive state rather than solely an acquired genetic endpoint
The colorectal-cancer biopsy, spatial-transcriptomic, and organoid study and the ATF3–asparagine study in resistant models and a patient-derived model show that the usual focus on acquired genetic lesions is incomplete: transcriptional, inflammatory, stress-response, and metabolic programs can arise early, coexist with subclonal genetic alterations, and themselves sustain resistance to KRAS G12C inhibitors. In the colorectal-cancer study, these states preceded progression and could be suppressed by targeting TBK1; in the other study, disrupting the ATF3–ASNS axis or upstream PERK restored drug sensitivity. This shifts resistance research toward detecting and treating dynamic, non-genetic cell states rather than waiting for or targeting only stable genomic escape routes 42167227May 42270775Jun.
KRAS activity can be regulated through farnesylation-driven liquid–liquid phase separation
The colon-cancer study of KRAS condensates identifies a role outside the set’s prevailing categories of direct inhibition, downstream pathway blockade, resistance profiling, and mutation detection: farnesylated KRAS forms cytoplasmic liquid–liquid phase-separated condensates that cluster RCE1, promote KRAS processing and plasma-membrane translocation, and amplify signaling. Statins, particularly pitavastatin, disrupted this condensate mechanism and enhanced G12C-inhibitor activity. The result adds subcellular phase organization and prenylation-dependent condensate control as a therapeutic entry point for KRAS-driven tumor growth 42202789May.
Papers
The 27 papers from the last 6 months that study KRAS G12C directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.
By theme
KRAS Inhibition in Lung Cancer (13)
- PRMT1 blockade reverts resistance to KRAS (G12C) inhibition through modulating ferroptosis signalling. International journal of oncology · 13 Nov 2026 PMID 43023238
- Random forest approach to predict genes correlated with adaptive responses to KRASG12C inhibitor. PloS one · 11 Nov 2026 PMID 43013488
- Expanding the RAS-verse: Novel Inhibitors, Emergent Dependencies, Fresh Opportunities in RAS-Mutant NSCLC. Cancer discovery · 2 Nov 2026 PMID 42968650
- Benzisothiazole derivatives as KRAS G12C inhibitors for potential treatment of non-small cell lung cancer. Bioorganic chemistry · 12 Oct 2026 PMID 42863233
- FAK inhibitor and RAF/MEK clamp avutometinib enhance KRAS G12C inhibitor efficacy in preclinical models of non-small cell lung cancer. Science translational medicine · 30 Sept 2026 PMID 42814800
- One-pot SP-EXPAR-integrated CRISPR/Cas14a assay for highly specific and versatile detection of ctDNA mutations in lung cancer patients. Analytical methods : advancing methods and applications · 24 Aug 2026 PMID 42635115
- Incidence of KRAS G12C mutations in genitourinary malignancies; emerging target in precision medicine. Oncotarget · 19 Aug 2026 PMID 42615885
- Integrated computational and preclinical evaluation of drug repurposing candidates for KRAS-mutant non-small cell lung cancer. Scientific reports · 13 Aug 2026 PMID 42595781
- Property-Biased Covalent DNA-Encoded Library Screening Enabled the Discovery of AM-8719, A Structurally Novel, CNS-Penetrant KRAS G12C Inhibitor. Journal of medicinal chemistry · 13 Aug 2026 PMID 42593915
- Signal logic gate mediated by a controllable CRISPR/Cas12a system for simultaneous detection of DNA mutation and methylation. Analytical methods : advancing methods and applications · 16 Jul 2026 PMID 42459132
- Amphiregulin-mediated EGFR activation drives both intrinsic and acquired resistance to KRAS G12C inhibitors in KRAS G12C-mutant non-small cell lung cancer. Oncogene · 2 Jul 2026 PMID 42393288
- Identification of Noncovalent Small-Molecules from Virtual Screening Toward the Development of Potential KRAS Inhibitors. Journal of chemical information and modeling · 26 Jun 2026 PMID 42359553
- Stability-Based Proteomic Methods Add Value to Activity-Based Protein Profiling Studies. ACS chemical biology · 11 Jun 2026 PMID 42275002
KRAS Resistance in Digestive Cancers (6)
- The KRAS targeting revolution in metastatic pancreatic cancer: insights from the landmark RASolute-302 trial and emerging allele-specific strategies at ASCO 2026. Journal of hematology & oncology · 8 Aug 2026 PMID 42571010
- Higher frequency of subclonal anti-EGFR resistance mutations in post-treatment samples from patients with colorectal cancer liver metastases following anti-EGFR-based conversion chemotherapy. PloS one · 6 Jul 2026 PMID 42406708
- The cartography of KRAS inhibitor resistance in colorectal cancer. Cancer cell · 11 Jun 2026 PMID 42276046
- Farnesylation-driven KRAS phase separation promotes colon tumor growth. Cell · 27 May 2026 PMID 42202789
- Targeted KRASG12V Degradation in vivo Elicits Lung Adenocarcinoma Regression with Subsequent Relapse from Dysregulated Proteolysis. Cancer research · 27 May 2026 PMID 42200804
- Concurrent genetic and non-genetic resistance mechanisms to KRAS inhibition in colorectal cancer. Cancer cell · 21 May 2026 PMID 42167227
SOS1 Inhibition in KRAS Cancer (4)
- Rat sarcoma inhibitors in and beyond gynecologic malignancies. Current opinion in obstetrics & gynecology · 24 Oct 2026 PMID 42924896
- EML4-ALK Mediates Resistance to KRASG12C Inhibition and Induces an Oncogenic Dependency by Rewiring Signaling through the Wild-Type RAS Pathway. Cancer discovery · 22 Jun 2026 PMID 42329099
- Discovery of CNS Penetrant SOS1 Inhibitors for the Treatment of KRAS-Dependent Cancers. Journal of medicinal chemistry · 16 Jun 2026 PMID 42301273
- Discovery of Highly Potent and Selective SOS1 Inhibitors for the Treatment of KRAS-Driven Colorectal Cancer. Journal of medicinal chemistry · 5 Jun 2026 PMID 42247371
Others — Precision Oncology Therapeutics (4)
- A Living Multi-Omics PDX Biobank of High-Risk Sarcomas Reveals ecDNA-Driven Oncogene Amplification in Osteosarcoma and Enables Preclinical Precision Oncology. Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 13 Oct 2026 PMID 42864811
- Forging New Pathways in Oncology: Strategic Insights from the 17th Annual Frontiers in Cancer Science Conference. Cancer research · 2 Jul 2026 PMID 42388021
- The dynamic evolution of circulating tumor cells during glecirasib treatment predicts survival and resistance in gastrointestinal tumors with KRASG12C mutation. Human cell · 1 Jul 2026 PMID 42384131
- Targeting ATF3-mediated asparagine biosynthesis reverses acquired resistance to KRASG12C inhibitors. Oncogene · 10 Jun 2026 PMID 42270775
By study type
Observational studies and case reports (1)
- Higher frequency of subclonal anti-EGFR resistance mutations in post-treatment samples from patients with colorectal cancer liver metastases following anti-EGFR-based conversion chemotherapy. PloS one · 6 Jul 2026 PMID 42406708
Human data, design not indexed (7)
- One-pot SP-EXPAR-integrated CRISPR/Cas14a assay for highly specific and versatile detection of ctDNA mutations in lung cancer patients. Analytical methods : advancing methods and applications · 24 Aug 2026 PMID 42635115
- Incidence of KRAS G12C mutations in genitourinary malignancies; emerging target in precision medicine. Oncotarget · 19 Aug 2026 PMID 42615885
- The KRAS targeting revolution in metastatic pancreatic cancer: insights from the landmark RASolute-302 trial and emerging allele-specific strategies at ASCO 2026. Journal of hematology & oncology · 8 Aug 2026 PMID 42571010
- Signal logic gate mediated by a controllable CRISPR/Cas12a system for simultaneous detection of DNA mutation and methylation. Analytical methods : advancing methods and applications · 16 Jul 2026 PMID 42459132
- Forging New Pathways in Oncology: Strategic Insights from the 17th Annual Frontiers in Cancer Science Conference. Cancer research · 2 Jul 2026 PMID 42388021
- The dynamic evolution of circulating tumor cells during glecirasib treatment predicts survival and resistance in gastrointestinal tumors with KRASG12C mutation. Human cell · 1 Jul 2026 PMID 42384131
- The cartography of KRAS inhibitor resistance in colorectal cancer. Cancer cell · 11 Jun 2026 PMID 42276046
Preclinical: animal, cell and lab studies (15)
- PRMT1 blockade reverts resistance to KRAS (G12C) inhibition through modulating ferroptosis signalling. International journal of oncology · 13 Nov 2026 PMID 43023238
- Random forest approach to predict genes correlated with adaptive responses to KRASG12C inhibitor. PloS one · 11 Nov 2026 PMID 43013488
- Expanding the RAS-verse: Novel Inhibitors, Emergent Dependencies, Fresh Opportunities in RAS-Mutant NSCLC. Cancer discovery · 2 Nov 2026 PMID 42968650
- Benzisothiazole derivatives as KRAS G12C inhibitors for potential treatment of non-small cell lung cancer. Bioorganic chemistry · 12 Oct 2026 PMID 42863233
- FAK inhibitor and RAF/MEK clamp avutometinib enhance KRAS G12C inhibitor efficacy in preclinical models of non-small cell lung cancer. Science translational medicine · 30 Sept 2026 PMID 42814800
- Integrated computational and preclinical evaluation of drug repurposing candidates for KRAS-mutant non-small cell lung cancer. Scientific reports · 13 Aug 2026 PMID 42595781
- Property-Biased Covalent DNA-Encoded Library Screening Enabled the Discovery of AM-8719, A Structurally Novel, CNS-Penetrant KRAS G12C Inhibitor. Journal of medicinal chemistry · 13 Aug 2026 PMID 42593915
- Amphiregulin-mediated EGFR activation drives both intrinsic and acquired resistance to KRAS G12C inhibitors in KRAS G12C-mutant non-small cell lung cancer. Oncogene · 2 Jul 2026 PMID 42393288
- Identification of Noncovalent Small-Molecules from Virtual Screening Toward the Development of Potential KRAS Inhibitors. Journal of chemical information and modeling · 26 Jun 2026 PMID 42359553
- EML4-ALK Mediates Resistance to KRASG12C Inhibition and Induces an Oncogenic Dependency by Rewiring Signaling through the Wild-Type RAS Pathway. Cancer discovery · 22 Jun 2026 PMID 42329099
- Discovery of CNS Penetrant SOS1 Inhibitors for the Treatment of KRAS-Dependent Cancers. Journal of medicinal chemistry · 16 Jun 2026 PMID 42301273
- Stability-Based Proteomic Methods Add Value to Activity-Based Protein Profiling Studies. ACS chemical biology · 11 Jun 2026 PMID 42275002
- Discovery of Highly Potent and Selective SOS1 Inhibitors for the Treatment of KRAS-Driven Colorectal Cancer. Journal of medicinal chemistry · 5 Jun 2026 PMID 42247371
- Farnesylation-driven KRAS phase separation promotes colon tumor growth. Cell · 27 May 2026 PMID 42202789
- Concurrent genetic and non-genetic resistance mechanisms to KRAS inhibition in colorectal cancer. Cancer cell · 21 May 2026 PMID 42167227
Unclassified: not yet indexed with MeSH (4)
- Rat sarcoma inhibitors in and beyond gynecologic malignancies. Current opinion in obstetrics & gynecology · 24 Oct 2026 PMID 42924896
- A Living Multi-Omics PDX Biobank of High-Risk Sarcomas Reveals ecDNA-Driven Oncogene Amplification in Osteosarcoma and Enables Preclinical Precision Oncology. Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 13 Oct 2026 PMID 42864811
- Targeting ATF3-mediated asparagine biosynthesis reverses acquired resistance to KRASG12C inhibitors. Oncogene · 10 Jun 2026 PMID 42270775
- Targeted KRASG12V Degradation in vivo Elicits Lung Adenocarcinoma Regression with Subsequent Relapse from Dysregulated Proteolysis. Cancer research · 27 May 2026 PMID 42200804
Written from 27 PubMed abstracts, each one listed by PMID above. Published: 2026-07-23. Last written: 2026-08-26 by GPT. Drafted by language models from published abstracts; not medical advice.